DEA Eases Requirements for Cannabidiol Trials

Now, a previously registered cannabidiol clinical researcher who is granted a waiver can readily modify his or her protocol and continue the research seamlessly.

The U.S. Drug Enforcement Administration announced Dec. 23 that it has eased some of the regulatory requirements imposed by the Controlled Substances Act for those who are conducting FDA-approved clinical trials on cannabidiol, an extract of the marijuana plant, to streamline the research process on its possible medicinal value and help foster ongoing scientific studies. DEA has notified affected researchers by letter of the changes, which took effect immediately.

A federal regulation, 21 CFR 1301.18, requires researchers conducting these clinical trials under an FDA Investigational New Drug Application to have a DEA research registration, which permits the possession of an approved amount of cannabidiol for a specific research protocol. Until now, researchers who expanded the scope of their studies and needed more of it than they were initially approved for had to request in writing a modification to their DEA research registrations. This could delay their research as the approval process included both DEA and the Food and Drug Administration.

Now, a previously registered cannabidiol clinical researcher who is granted a waiver can readily modify his or her protocol and continue the research seamlessly.

"Marijuana is a Schedule I controlled substance because of the presence of tetrahydrocannabinol (THC), marijuana's psychoactive ingredient," according to DEA's news release. "Because CBD contains less than 1 percent THC and has shown some potential medicinal value, there is great interest in studying it for medical applications. Currently, CBD is a Schedule I controlled substance as defined under the CSA. Though the FDA approves drugs for medical use in the United States, the DEA regulates the handling of all controlled substances, including those being used by researchers to conduct studies."

Download Center

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • Online Safety Training Buyer's Guide

    Use this handy buyer's guide to learn the basics of selecting online safety training and how to use it at your workplace.

  • COVID Return-to-Work Checklist, Fall 2021

    Use this checklist as an aid to help your organization return to work during the COVID-19 pandemic in a safe and healthy manner.

  • SDS Buyer's Guide

    Learn to make informed decisions while searching for SDS Management Software.

  • Risk Matrix Guide

    Risk matrices come in many different shapes and sizes. Understanding the components of a risk matrix will allow you and your organization to manage risk effectively.

  • Industry Safe

Featured Whitepapers

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2021

    October 2021

    Featuring:

    • TRAINING
      On Route To Safe Material Handling
    • SAFETY CULTURE
      Normalization of Deviations in Performance
    • IH:INDOOR AIR QUALITY
      Arresting Fugitive Dusts
    • PPE:FOOT PROTECTION
      Safety Shoes Make the Outfit for Well-Protected Workers
    View This Issue